Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MANDEL, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MANDEL, W.
(Chest. 1959;36:293-296.)
© 1959 American College of Chest Physicians

Pyridoxine and the Isoniazid-Induced Neuropathy

WILLIAM MANDEL M.D.1

1 The Department of Medicine, University of California, School of Medicine and University of California Tuberculosis Service, San Francisco Hospital.

The isoniazid-induced peripheral neuropathy occurring in adult tuberculous patients results from a deficiency of biologically active pyridoxine. The deficiency is caused by the combination of isoniazid and pyridoxine to form a hydrazone which is excreted in the urine. It can be prevented by administration of pyridoxine whenever isoniazid is given. A 10 mg. dose of pyridoxine for each 100 mg. of isoniazid appears adequate to prevent both clinical and potential subclinical manifestations of pyridoxine deficiency. The administration of pyridoxine does not interfere with the antituberculous action of isoniazid.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1959 by the American College of Chest Physicians.